[{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"67575df3-fe79-49cd-97ab-2aa59bfde6c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02359565","created_at":"2021-01-18T11:13:52.172Z","updated_at":"2025-02-25T16:58:45.335Z","phase":"Phase 1","brief_title":"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma","source_id_and_acronym":"NCT02359565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2025-02-03"},{"id":"7460cc37-d435-44b0-a888-a97d57a2e6c3","acronym":"START-001","url":"https://clinicaltrials.gov/study/NCT05592626","created_at":"2022-10-24T13:57:11.728Z","updated_at":"2025-02-25T17:31:39.938Z","phase":"Phase 1/2","brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05592626 - START-001","lead_sponsor":"Marengo Therapeutics, Inc.","biomarkers":" KRAS • TMB • MSI • RAS","pipe":" | ","alterations":" KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type","tags":["KRAS • TMB • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e invikafusp alfa (STAR0602)"],"overall_status":"Recruiting","enrollment":" Enrollment 365","initiation":"Initiation: 01/04/2023","start_date":" 01/04/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-30"},{"id":"d5cf9deb-5221-48da-8860-edd0ad9556de","acronym":"IMperator","url":"https://clinicaltrials.gov/study/NCT06331598","created_at":"2025-02-26T08:19:48.665Z","updated_at":"2025-02-26T08:19:48.665Z","phase":"Phase 2","brief_title":"A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)","source_id_and_acronym":"NCT06331598 - IMperator","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 10/20/2028","primary_completion_date":" 10/20/2028","study_txt":" Completion: 09/20/2029","study_completion_date":" 09/20/2029","last_update_posted":"2024-12-24"},{"id":"a7d87c22-61ed-4880-930a-7f94876963f9","acronym":"KEYNOTE-E64","url":"https://clinicaltrials.gov/study/NCT04787042","created_at":"2021-03-08T12:53:50.679Z","updated_at":"2025-02-25T16:11:14.799Z","phase":"Phase 1/2","brief_title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","source_id_and_acronym":"NCT04787042 - KEYNOTE-E64","lead_sponsor":"Simcha IL-18, Inc.","biomarkers":" ALK • TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR • ALK positive • ALK mutation","tags":["ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-15"},{"id":"335041a2-cf72-4beb-950a-50b3ecd1dce6","acronym":"KEYNOTE A99","url":"https://clinicaltrials.gov/study/NCT04198766","created_at":"2021-01-18T20:27:39.735Z","updated_at":"2025-02-25T16:09:43.736Z","phase":"Phase 1/2","brief_title":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)","source_id_and_acronym":"NCT04198766 - KEYNOTE A99","lead_sponsor":"Inhibrx Biosciences, Inc","biomarkers":" EGFR • PD-L1 • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 333","initiation":"Initiation: 12/10/2019","start_date":" 12/10/2019","primary_txt":" Primary completion: 02/02/2026","primary_completion_date":" 02/02/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2024-07-19"},{"id":"607c59af-1fd9-4afc-8491-e33c116441ac","acronym":"PNeoVCA","url":"https://clinicaltrials.gov/study/NCT05269381","created_at":"2022-03-08T17:52:43.258Z","updated_at":"2024-07-02T16:34:26.810Z","phase":"Phase 1/2","brief_title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05269381 - PNeoVCA","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK","pipe":" | ","alterations":" TMB-H","tags":["KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 02/24/2025","primary_completion_date":" 02/24/2025","study_txt":" Completion: 02/24/2026","study_completion_date":" 02/24/2026","last_update_posted":"2024-06-12"},{"id":"786f4600-19b5-4661-828d-06dd8c75ce47","acronym":"QuEST1","url":"https://clinicaltrials.gov/study/NCT03493945","created_at":"2021-12-08T18:56:16.054Z","updated_at":"2024-07-02T16:34:37.137Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","source_id_and_acronym":"NCT03493945 - QuEST1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • BRCA1 • BRCA2 • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"7fc0fb06-d255-4be4-aba4-ae25c5e3da72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04087018","created_at":"2021-02-09T08:59:18.309Z","updated_at":"2024-07-02T16:35:00.967Z","phase":"Phase 1","brief_title":"Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04087018","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/24/2019","start_date":" 09/24/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-24"},{"id":"4bdb8b24-ba90-4230-8729-5ed16999e8ca","acronym":"KEYNOTE-051","url":"https://clinicaltrials.gov/study/NCT02332668","created_at":"2021-01-18T11:04:27.461Z","updated_at":"2024-07-02T16:35:02.096Z","phase":"Phase 1/2","brief_title":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","source_id_and_acronym":"NCT02332668 - KEYNOTE-051","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 03/18/2015","start_date":" 03/18/2015","primary_txt":" Primary completion: 10/25/2027","primary_completion_date":" 10/25/2027","study_txt":" Completion: 10/25/2027","study_completion_date":" 10/25/2027","last_update_posted":"2024-05-22"},{"id":"6a682511-2191-4433-84ad-3eecf572d062","acronym":"","url":"https://clinicaltrials.gov/study/NCT05093231","created_at":"2021-10-26T21:53:09.463Z","updated_at":"2024-07-02T16:35:02.607Z","phase":"Phase 2","brief_title":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT05093231","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/17/2024","start_date":" 06/17/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 05/04/2026","study_completion_date":" 05/04/2026","last_update_posted":"2024-05-20"},{"id":"bf08ec17-5171-4452-9f04-c52123ce8ca4","acronym":"QUILT-3.017","url":"https://clinicaltrials.gov/study/NCT03476681","created_at":"2021-10-22T17:53:23.788Z","updated_at":"2024-07-02T16:35:03.580Z","phase":"Phase 1/2","brief_title":"Study of NEO-201 in Solid Tumors Expansion Cohorts","source_id_and_acronym":"NCT03476681 - QUILT-3.017","lead_sponsor":"Precision Biologics, Inc","biomarkers":" EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600","tags":["EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NEO-201"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 10/15/2025","primary_completion_date":" 10/15/2025","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-05-15"},{"id":"4f044f18-3e23-4009-90ad-d13973fbf09d","acronym":"KEYNOTE-158","url":"https://clinicaltrials.gov/study/NCT02628067","created_at":"2021-01-17T17:22:08.805Z","updated_at":"2024-07-02T16:35:04.350Z","phase":"Phase 2","brief_title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","source_id_and_acronym":"NCT02628067 - KEYNOTE-158","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1609","initiation":"Initiation: 12/18/2015","start_date":" 12/18/2015","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2024-05-10"},{"id":"993731ff-6955-4714-a314-4cb1c19a566a","acronym":"MOAB","url":"https://clinicaltrials.gov/study/NCT06069726","created_at":"2023-10-06T14:11:22.097Z","updated_at":"2024-07-02T16:35:09.097Z","phase":"Phase 2","brief_title":"A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial","source_id_and_acronym":"NCT06069726 - MOAB","lead_sponsor":"Duke University","biomarkers":" TMB • CD4","pipe":" | ","alterations":" TMB-H • IDH wild-type","tags":["TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/21/2024","start_date":" 03/21/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-17"},{"id":"322df34a-767e-4d5e-a452-b969475bc657","acronym":"INSPIRE","url":"https://clinicaltrials.gov/study/NCT04717154","created_at":"2021-01-24T15:53:02.001Z","updated_at":"2025-02-25T14:29:51.746Z","phase":"Phase 2","brief_title":"Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT04717154 - INSPIRE","lead_sponsor":"Radboud University Medical Center","biomarkers":" TMB • BRCA2 • CDK12","pipe":" | ","alterations":" TMB-H","tags":["TMB • BRCA2 • CDK12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 01/19/2021","start_date":" 01/19/2021","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 02/15/2026","study_completion_date":" 02/15/2026","last_update_posted":"2024-04-16"},{"id":"8fc7055a-dde1-4071-9f3b-d016eed452de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891198","created_at":"2021-05-18T12:02:07.091Z","updated_at":"2024-07-02T16:35:11.517Z","phase":"Phase 2","brief_title":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04891198","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-03"},{"id":"c74db0f2-c326-4bee-b78b-ae95a71b7f43","acronym":"","url":"https://clinicaltrials.gov/study/NCT06036745","created_at":"2023-09-14T15:13:27.955Z","updated_at":"2024-07-02T16:35:15.933Z","phase":"Phase 2","brief_title":"Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen","source_id_and_acronym":"NCT06036745","lead_sponsor":"Shanghai Minimally Invasive Surgery Center","biomarkers":" PD-L1 • TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR • PD-L1 overexpression","tags":["PD-L1 • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-03-07"},{"id":"8b035599-60c6-4e12-a848-25b7b29e695c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005728","created_at":"2021-08-13T12:53:42.693Z","updated_at":"2024-07-02T16:35:16.340Z","phase":"Phase 2","brief_title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05005728","lead_sponsor":"Xencor, Inc.","biomarkers":" TMB • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-05"},{"id":"6151f3df-8e2e-4964-850d-c170b0c3a37a","acronym":"DART","url":"https://clinicaltrials.gov/study/NCT04392505","created_at":"2021-01-18T21:12:06.849Z","updated_at":"2025-02-25T14:59:05.750Z","phase":"Phase 2","brief_title":"Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study","source_id_and_acronym":"NCT04392505 - DART","lead_sponsor":"Oslo University Hospital","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H • TMB-L","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • TMB-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2024-02-29"},{"id":"b7a36882-65b3-44a2-abdd-b0fe4500256d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03809624","created_at":"2021-07-22T21:52:31.520Z","updated_at":"2024-07-02T16:35:18.390Z","phase":"Phase 2","brief_title":"Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer","source_id_and_acronym":"NCT03809624","lead_sponsor":"Inhibrx, Inc.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enristomig (INBRX-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-21"},{"id":"0f852cf8-74ca-4cab-8733-92bf79da5210","acronym":"","url":"https://clinicaltrials.gov/study/NCT03671720","created_at":"2021-01-18T18:00:41.360Z","updated_at":"2024-07-02T16:35:20.464Z","phase":"Phase 1","brief_title":"Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden","source_id_and_acronym":"NCT03671720","lead_sponsor":"Capital Medical University","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/11/2018","start_date":" 09/11/2018","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-02-07"},{"id":"92b08398-0806-48cd-ac81-b41a6d71f436","acronym":"BIOLUMA","url":"https://clinicaltrials.gov/study/NCT03083691","created_at":"2021-01-18T15:11:28.241Z","updated_at":"2025-02-25T14:37:24.127Z","phase":"Phase 2","brief_title":"BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer","source_id_and_acronym":"NCT03083691 - BIOLUMA","lead_sponsor":"Lung Cancer Group Cologne","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 11/20/2023","study_completion_date":" 11/20/2023","last_update_posted":"2024-01-17"}]